Overview

A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)

Status:
Completed

Trial end date:
2015-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to define a safe dose of AC220 when given as maintenance therapy after treatment with an allogeneic stem cell transplant.

Phase:

Phase 1

Details

Lead Sponsor:

Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.

Collaborator:

Ambit Biosciences Corporation